Jilin Aodong Pharmaceutical Group Co Ltd

SHE:000623 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.04 Billion
CN¥22.32 Billion CNY
Market Cap Rank
#4895 Global
#562 in China
Share Price
CN¥18.66
Change (1 day)
+0.65%
52-Week Range
CN¥15.16 - CN¥21.82
All Time High
CN¥24.39
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Jilin Aodong Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in China. The company provides various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, tonic medicines, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine. It is also involved in … Read more

Jilin Aodong Pharmaceutical Group Co Ltd (000623) - Net Assets

Latest net assets as of September 2025: CN¥30.82 Billion CNY

Based on the latest financial reports, Jilin Aodong Pharmaceutical Group Co Ltd (000623) has net assets worth CN¥30.82 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥34.58 Billion) and total liabilities (CN¥3.76 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥30.82 Billion
% of Total Assets 89.13%
Annual Growth Rate 20.53%
5-Year Change 24.45%
10-Year Change 66.53%
Growth Volatility 34.96

Jilin Aodong Pharmaceutical Group Co Ltd - Net Assets Trend (1993–2024)

This chart illustrates how Jilin Aodong Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Jilin Aodong Pharmaceutical Group Co Ltd (1993–2024)

The table below shows the annual net assets of Jilin Aodong Pharmaceutical Group Co Ltd from 1993 to 2024.

Year Net Assets Change
2024-12-31 CN¥29.28 Billion +6.48%
2023-12-31 CN¥27.50 Billion +4.40%
2022-12-31 CN¥26.34 Billion +5.20%
2021-12-31 CN¥25.04 Billion +6.42%
2020-12-31 CN¥23.53 Billion +4.83%
2019-12-31 CN¥22.44 Billion +5.65%
2018-12-31 CN¥21.24 Billion +3.45%
2017-12-31 CN¥20.54 Billion +8.81%
2016-12-31 CN¥18.87 Billion +7.34%
2015-12-31 CN¥17.58 Billion +38.90%
2014-12-31 CN¥12.66 Billion +18.80%
2013-12-31 CN¥10.66 Billion +9.25%
2012-12-31 CN¥9.75 Billion +7.24%
2011-12-31 CN¥9.09 Billion +25.52%
2010-12-31 CN¥7.25 Billion +10.45%
2009-12-31 CN¥6.56 Billion +27.56%
2008-12-31 CN¥5.14 Billion +5.09%
2007-12-31 CN¥4.89 Billion +137.10%
2006-12-31 CN¥2.06 Billion +22.05%
2005-12-31 CN¥1.69 Billion +3.62%
2004-12-31 CN¥1.63 Billion +20.80%
2003-12-31 CN¥1.35 Billion +10.30%
2002-12-31 CN¥1.22 Billion +3.60%
2001-12-31 CN¥1.18 Billion +6.76%
2000-12-31 CN¥1.11 Billion +53.73%
1999-12-31 CN¥720.42 Million +13.30%
1998-12-31 CN¥635.85 Million +91.24%
1997-12-31 CN¥332.48 Million +36.79%
1996-12-31 CN¥243.07 Million +135.94%
1995-12-31 CN¥103.02 Million +29.05%
1994-12-31 CN¥79.83 Million -10.99%
1993-12-31 CN¥89.69 Million --

Equity Component Analysis

This analysis shows how different components contribute to Jilin Aodong Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1978450091500.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥19.78 Billion 68.16%
Common Stock CN¥1.20 Billion 4.12%
Other Comprehensive Income CN¥7.30 Billion 25.15%
Other Components CN¥746.80 Million 2.57%
Total Equity CN¥29.03 Billion 100.00%

Jilin Aodong Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Jilin Aodong Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company Market Cap
OrangePL
WAR:OPL
 		$2.05 Billion
Beijing Orient Landscape Co Ltd
SHE:002310
 		$2.06 Billion
OATLY GROUP AB SP.ADS/1
F:9ZX
 		$2.06 Billion
Hubei Zhenhua Chemical Co Ltd
SHG:603067
 		$2.06 Billion
SWCC SHOWA HLDGS CO. LTD.
F:7VY
 		$2.05 Billion
PTT Global Chemical Public Company Limited
OTCGREY:PTGCF
 		$2.05 Billion
Luoyang Xinqianglian Slewing Bearin
SHE:300850
 		$2.05 Billion
G-bits Network Technology Xiamen Co Ltd
SHG:603444
 		$2.05 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jilin Aodong Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 27,211,602,992 to 29,027,588,245, a change of 1,815,985,253 (6.7%).
  • Net income of 1,551,393,071 contributed positively to equity growth.
  • Dividend payments of 1,059,989,000 reduced retained earnings.
  • Share repurchases of 300,004,613 reduced equity.
  • Other comprehensive income increased equity by 148,663,903.
  • Other factors increased equity by 1,475,921,892.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥1.55 Billion +5.34%
Dividends Paid CN¥1.06 Billion -3.65%
Share Repurchases CN¥300.00 Million -1.03%
Other Comprehensive Income CN¥148.66 Million +0.51%
Other Changes CN¥1.48 Billion +5.08%
Total Change CN¥- 6.67%

Book Value vs Market Value Analysis

This analysis compares Jilin Aodong Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.76x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 210.90x to 0.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 CN¥0.09 CN¥18.66 x
1996-12-31 CN¥0.21 CN¥18.66 x
1997-12-31 CN¥0.29 CN¥18.66 x
1998-12-31 CN¥0.50 CN¥18.66 x
1999-12-31 CN¥0.57 CN¥18.66 x
2000-12-31 CN¥0.92 CN¥18.66 x
2001-12-31 CN¥0.98 CN¥18.66 x
2002-12-31 CN¥0.91 CN¥18.66 x
2003-12-31 CN¥1.02 CN¥18.66 x
2004-12-31 CN¥1.12 CN¥18.66 x
2005-12-31 CN¥1.19 CN¥18.66 x
2006-12-31 CN¥1.53 CN¥18.66 x
2007-12-31 CN¥3.96 CN¥18.66 x
2008-12-31 CN¥4.16 CN¥18.66 x
2009-12-31 CN¥5.37 CN¥18.66 x
2010-12-31 CN¥6.18 CN¥18.66 x
2011-12-31 CN¥7.77 CN¥18.66 x
2012-12-31 CN¥8.29 CN¥18.66 x
2013-12-31 CN¥9.07 CN¥18.66 x
2014-12-31 CN¥10.84 CN¥18.66 x
2015-12-31 CN¥14.95 CN¥18.66 x
2016-12-31 CN¥16.22 CN¥18.66 x
2017-12-31 CN¥17.46 CN¥18.66 x
2018-12-31 CN¥18.09 CN¥18.66 x
2019-12-31 CN¥17.39 CN¥18.66 x
2020-12-31 CN¥18.30 CN¥18.66 x
2021-12-31 CN¥19.75 CN¥18.66 x
2022-12-31 CN¥20.02 CN¥18.66 x
2023-12-31 CN¥22.87 CN¥18.66 x
2024-12-31 CN¥24.66 CN¥18.66 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jilin Aodong Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 5.34%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 59.43%
  • • Asset Turnover: 0.08x
  • • Equity Multiplier: 1.14x
  • Recent ROE (5.34%) is below the historical average (13.11%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 25.18% 14.98% 0.70x 2.40x CN¥15.63 Million
1996 16.30% 16.33% 0.58x 1.73x CN¥15.32 Million
1997 26.89% 27.06% 0.59x 1.68x CN¥56.17 Million
1998 13.87% 22.16% 0.43x 1.44x CN¥22.77 Million
1999 15.02% 26.02% 0.32x 1.78x CN¥33.54 Million
2000 7.54% 25.80% 0.22x 1.33x CN¥-26.40 Million
2001 2.83% 7.28% 0.29x 1.36x CN¥-81.99 Million
2002 7.12% 13.17% 0.30x 1.77x CN¥-30.54 Million
2003 8.37% 14.71% 0.35x 1.65x CN¥-19.23 Million
2004 8.96% 14.24% 0.33x 1.93x CN¥-13.61 Million
2005 8.00% 14.40% 0.30x 1.82x CN¥-27.66 Million
2006 27.44% 63.25% 0.26x 1.69x CN¥309.63 Million
2007 43.23% 235.73% 0.15x 1.22x CN¥1.53 Billion
2008 17.79% 92.86% 0.16x 1.19x CN¥377.18 Million
2009 21.84% 133.25% 0.14x 1.14x CN¥740.67 Million
2010 17.24% 111.17% 0.14x 1.10x CN¥519.93 Million
2011 21.98% 173.07% 0.11x 1.12x CN¥1.08 Billion
2012 6.68% 44.72% 0.13x 1.13x CN¥-320.81 Million
2013 10.01% 54.11% 0.16x 1.14x CN¥1.25 Million
2014 11.21% 62.97% 0.16x 1.09x CN¥152.57 Million
2015 14.92% 111.09% 0.12x 1.14x CN¥855.71 Million
2016 8.94% 60.89% 0.13x 1.09x CN¥-197.42 Million
2017 9.18% 62.60% 0.14x 1.08x CN¥-166.50 Million
2018 4.45% 28.13% 0.13x 1.17x CN¥-1.17 Billion
2019 6.31% 45.45% 0.12x 1.16x CN¥-821.31 Million
2020 7.32% 75.89% 0.08x 1.17x CN¥-626.43 Million
2021 7.16% 77.29% 0.08x 1.17x CN¥-705.45 Million
2022 6.84% 62.09% 0.09x 1.20x CN¥-822.86 Million
2023 5.36% 42.33% 0.11x 1.19x CN¥-1.26 Billion
2024 5.34% 59.43% 0.08x 1.14x CN¥-1.35 Billion

Industry Comparison

This section compares Jilin Aodong Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,236,936,156
  • Average return on equity (ROE) among peers: -1.06%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jilin Aodong Pharmaceutical Group Co Ltd (000623) CN¥30.82 Billion 25.18% 0.12x $2.05 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million